Program overview

Print program
Thursday November 28, 2024Friday November 29, 2024

Closure

Time: 16:00 - 16:00 CET

Closing remarks

Time: 15:45 - 16:00 CET

Paul Capel Prize – Basic Science

Time: 15:30 - 15:45 CET

State of the Art III – platelets

Time: 14:30 - 15:30 CET
No avatar
14:30-15:00 Platelets in post-myocardial infarction healing - Sandrine Horman
Belgium
No avatar
15:00-15:30 The molecular basis of heterogeneous platelet activation - Lorenzo Alberio
Switzerland

Educational II – genetics of VTE

Time: 13:45 - 14:30 CET
No avatar
Pierre-Emannuel Morange

Lunch break and Poster walk

Time: 12:45 - 13:45 CET

CSL Behring Encouragement Grant

Time: 12:30 - 12:45 CET

Oral Presentations Basic Science

Time: 11:30 - 12:30 CET
No avatar
11:30 O06 Targeting antigen-specific B cells in immune mediated thrombotic thrombocytopenic purpura using modular CAR T cells - Sara Rovira Puig
Belgium
No avatar
11:42 O07 imMKCL-based Glanzmann Thrombastenia models to study platelet formation and function - Kato Ramaekers
Belgium
No avatar
11:54 O08 Conformational opening of ADAMTS13 does not necessarily indicate preactivation of its metalloprotease domain - Quintijn Bonnez
Belgium
No avatar
12:06 O09 An in-house ex-vivo NETs induction model for the evaluation of potential NETosis inhibitors - Constant Gillot
Belgium
No avatar
12:18 O10 Sustainable polymers with improved biocompatibility: new materials for blood-contacting medical devices - Sofia F. Melo
Belgium

Coffee break

Time: 11:00 - 11:30 CET

Sponsored Satellite Symposium III – CSL Behring

Time: 10:00 - 11:00 CET

This symposium is intended for health care professionals only.

No avatar
10:05-10:20 Empowering choices in hemophilia care with gene therapy in sight: the patient’s association perspective - Sarah De Witte
Belgium
10:20-10:35 Empowering choices in hemophilia care with gene therapy in sight: the doctor’s approach - Peter Verhamme
Belgium
10:35-10:50 Empowering choices in hemophilia care with gene therapy in sight: the patient’s experience
Belgium
No avatar
10:50-11:00 Questions and answers and closing
No avatar
Welcome speech and introduction - Cedric Hermans
Belgium

Registration, Coffee & Networking

Time: 08:30 - 09:00 CET

Dinner

Time: 19:00 - 19:00 CET

Salons Van Dijck, Frederik de Merodestraat 33, Mechelen

Closure

Time: 17:45 - 17:45 CET

Paul Capel Prize – Clinical & Laboratory

Time: 17:30 - 17:45 CET

Professor Gaston Baele Memorial Lecture

Time: 16:45 - 17:30 CET
No avatar
What I would like to tell you about the BSTH - Serge Motte

Coffee break

Time: 16:15 - 16:45 CET

Sponsored Satellite Symposium II – Sobi

Time: 15:15 - 16:15 CET

RAISING THE BAR IN HAEMOPHILIA A CARE: THE WAY TOWARDS NORMALIZED HAEMOSTASIS

No avatar
15:15-15:40 The Clinical Perspective - Cédric Hermans
Belgium
No avatar
15:40-16:05 The Laboratory Perspective - Marie-Astrid van Dievoet
Belgium
No avatar
16:05-16:15 Q&A

State of the Art I – Thromboinflammation/immunothrombosis

Time: 14:15 - 15:15 CET
No avatar
14:15-14:45 DAMPS/procoagulant platelets/thrombo-inflammation - Julie Rayes
United Kingdom
No avatar
14:45-15:15 Neutrophils in Thrombosis - Benoit Ho-Tin
France

BSTH General Assembly

Time: 13:45 - 14:15 CET

Exclusively for members

Sponsored Satellite Symposium I – Octapharma

Time: 10:15 - 11:15 CET

Breaking Tradition: The Role of FVIII in Haemostasis and Beyond

No avatar
1 Welcome & Introduction - Cedric Hermans
Belgium
No avatar
2 FVIII Modification: Impact on Platelet Binding and Mediated Signalling - Anja Strebel
Switzerland
No avatar
3 FVIII Endothelial Cell Mediated Signalling - Antonia Follenzi
Italy
No avatar
4 Generating Long-Term Data on Bone and Joint Health: The PROVE Study - Sander Botter
Switzerland
No avatar
5 Generating Long-Term Data on Bone and Joint Health: The PROVE Study - Stephan Maack
Switzerland
No avatar
6 Q&A - Speakers and Audience

Welcome

Time: 09:15 - 09:28 CET

State of the Art II – new therapeutic options in intermediate- and high-risk PE: what, when, and how to choose?

Time: 09:00 - 10:00 CET
No avatar
09:00-09:30 Trombusaspiration as a novel therapeutic option for (sub)massive PE - Lawrence Bonne
Belgium
No avatar
09:30-10:00 Interventional or conservative approach: how to treat (sub)massive PE patients in 2025? - Menno Huisman
Netherlands

Oral presentations Clinical and Laboratory

Time: 11:45 - 12:45 CET
No avatar
11:45 O01 Multi-Gene Panel for Thrombophilia Testing in Venous Thromboembolism - Andreas Verstraete
Belgium
No avatar
11:57 O02 Diagnostic performance of commercial antithrombin activity assays: do we get what we expect? - Christelle Orlando
Belgium
No avatar
12:09 O03 Mendelian randomization implicates thromboembolism in the pathogenesis of long COVID - Art Schuermans
Belgium
No avatar
12:21 O04 Antithrombin deficiency: report of a rare case homozygous for p.Leu131Phe Heparin Binding Site mutation - Sara Cherkaoui
Belgium
No avatar
12:33 O05 In vitro testing of the anticoagulant capacity of rivaroxaban according to severity of liver disease - Jill Vercruyssen
Belgium

Lunch break and Poster walk

Time: 12:45 - 13:45 CET

Coffee break

Time: 11:15 - 11:45 CET

Educational I

Time: 09:30 - 10:15 CET
No avatar
Rebalancing agents in Haemophilia - Quentin Van Thillo
Belgium

Registration, Coffee, Networking

Time: 08:30 - 09:15 CET
Home › Program
Website and marketing